ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody Jun 18, 2008
TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels ... TB-403 (Anti-PIGF) has completed an initial Phase I clinical trial and recently received approval to enter a Phase Ib dose escalation trial. (PR Newswire)
ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell Nov 2, 2007
These attractive properties are due to PIGF inhibitors acting by blocking the formation of new blood vessels only in the cancer tissue. ThromboGenics and BioInvent have made the decision to advance their lead anti-PIGF monoclonal antibody, TB-403, into the clinic, and expect to start the first Phase I clinical trial by the end of 2007. (PR Newswire)
Cancer: Clinical Studies In The Pipeline Oct 29, 2007
Using protein arrays to test for angiogenic biomarkers in the blood, the investigators found that the levels of VEGF and PIGF increased, while that of soluble VEGFR2 declined in most patients. Also, flow cytometry analyses of blood cells suggested that circulating endothelial cells increased in some patients while circulating progenitor cells were significantly decreased, indicating that sunitinib may indeed target key angiogenesis pathways in relevant cell populations. (Science Daily)
Results of VEGF Trap (Aflibercept) Highlighted at ASCO 2007 Annual Meeting Jun 3, 2007
It blocks all VEGF-A isoforms plus placental growth factor (PIGF), another angiogenic growth factor that appears to play a role in tumor angiogenesis. The VEGF Trap has a relatively long half-life of approximately two weeks. (PR Newswire)
